Probiotic Bacteria for Infant IgA Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infants born via Cesarean section experience delayed colonization by beneficial bacteria, leading to potential adverse health consequences due to disrupted gut microbiota, which affects IgA secretion and mucosal immune development, differing from vaginally delivered infants.
Innovation Solution
Administration of probiotic bacteria, specifically strains like Lactobacillus and Bifidobacterium, in combination with prebiotics, to infants born via Cesarean section to promote early colonization by beneficial species, enhancing IgA secretion and mucosal immune defenses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infants are delivered by Cesarean section, then the birth process is faster and safer in certain medical conditions, but the gut microbiota colonization is delayed and disrupted
Solution Approach 1:
The patent applies preliminary action by administering probiotic bacteria to infants immediately after Cesarean section delivery. This early intervention establishes beneficial microbiota before the window for natural colonization closes, compensating for the missed vaginal delivery exposure and preventing subsequent microbiota disruption.
Solution Approach 2:
The patent uses probiotic bacteria as an intermediary to transfer the beneficial effects of vaginal delivery microbiota exposure. These probiotics serve as a mediator that replicates the protective microbiota establishment that would normally occur during vaginal delivery, bridging the gap created by Cesarean section.
2Reliability
If probiotic bacteria are administered to Cesarean section infants, then IgA secretion and mucosal immune defenses are enhanced, but additional intervention steps are required
Solution Approach 1:
The patent applies self-service by using naturally occurring probiotic bacteria that the infant's body can process and utilize without complex intervention systems. The probiotics self-colonize the gut and naturally stimulate the immune system to produce IgA, requiring only simple administration rather than complex medical devices or procedures.
3Stability of the object's composition
If vaginal delivery is performed, then natural microbiota colonization occurs immediately, but it is not always medically feasible or safe
Solution Approach 1:
The patent applies parameter changes by altering the timing and method of microbiota introduction. Instead of relying on the delivery method (vaginal vs. Cesarean), the invention changes the parameter of when and how microbiota is introduced - immediately after birth through probiotic administration, regardless of delivery method, thereby achieving consistent microbiota establishment across different medical scenarios.
Data Source
AI summary
Use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for increasing IgA secretion in an infant delivered by cesarean section during the first four months of the life of the infant.